glp-1 drugs and parkinson's disease Are we measuring the wrong primary outcome for for Parkinson's? Spoiler alert: the pooled data suggests we should pivot away from a motor outcome. Should we think cognitive, autonomic, sleep GLP-1 and Parkinson's Disease: Research,

Never inject into the same spot twice in a row

The Journal of Organic Chemistry, 85 (3), 1764-1768

Dietary administration of zinc inhibits the proangiogenic and invasive capabilities of metastatic prostate cancer cells

Marvin-Peek J , Atluri H, Short NJ, Maiti A, Takahashi K, Loghavi S, Lachowiez CA, Valero YA, Montalban-Bravo G, Sasaki K, Haddad FG, Issa GC, Masarova L, Abbas HA, Andreeff M , Borthakur G, Mullin J, Tippett GD, Chien KS, Hammond D, Ishizawa J, Jain N, Reville PK, Swaminathan M, Yilmaz M, Daver N, Kadia TM, Ravandi F, Garcia-Manero G, Kantarjian HM, DiNardo CD

injection of 50 mg/kg sodium pentobarbital (Sigma), and thoracic aorta was carefully dissected and maintained at 37 C in Krebs solution containing 118.2 mM NaCl, 4.7 mM KCl, 1.2 mM MgSO 4 , 25 mM NaHCO 3 , 1.2 mM KH 2 PO 4 , 1.9 mM CaCl 2 and 11.7 mM dextrose (pH 7.4, 95% O 2 , 5% CO 2 )